Chi Zhu is a postdoctoral fellow in the Näär Lab of Department of Nutritional Sciences & Toxicology at UC Berkeley. His research interests range from epigenetic/metabolic changes in cancer or chronic metabolic diseases to the development of antisense oligonucleotide (ASO)-based therapeutics. Chi received his Ph.D. at the Institute of Medical Science, the University of Tokyo in 2017, where he explored the mechanism of colon cancer occurrence and development, mainly focusing on the malfunction of Wnt signaling pathway. Chi’s recent work is focusing on the development of ASO-based therapeutics for COVID-19 and this study has already shown very promising anti-viral efficacy of ASO therapeutics both in vitro and in vivo. As a Sidney MacDonald Russell fellow, Chi will keep working on the optimization of both anti-viral efficacy and the drug delivery system of COVID-19 ASO therapeutics, and will expand his work developing the ASO therapeutics to pan-coronaviruses and other viral respiratory diseases.